ID
17655
Descrição
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palavras-chave
Versões (2)
- 01/08/2016 01/08/2016 -
- 27/09/2016 27/09/2016 -
Transferido a
27 de setembro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descrição
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Descrição
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [1,2]
- C0221743 (Skin reaction)
- SNOMED
- 251348006
- UMLS CUI [2,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [2,2]
- C0018500 (Hair Diseases)
- SNOMED
- 279425004
- UMLS CUI [3,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [3,2]
- C0234909 (Nail changes)
- SNOMED
- 416596008
Descrição
Indication Prophylaxis
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C3146298 (Indication)
- UMLS CUI [1,2]
- C0199176 (Prophylactic treatment)
- SNOMED
- 360271000
Descrição
Drug Administration Route
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Descrição
Drug Administration Route
Tipo de dados
text
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Descrição
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Descrição
Indication
Tipo de dados
text
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Descrição
Date Started
Tipo de dados
date
Alias
- UMLS CUI [1]
- C3173309 (Date treatment or therapy started)
- LOINC
- LP262646-5
Descrição
Date Stopped
Tipo de dados
date
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Descrição
Date Stopped
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Similar models
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])
Sem comentários